The present study aimed to produce an mRNA vaccine and analyze two types of vectors. According to this study, the Food and Drug Administration has fully approved the mRNA vaccine as the most effective vaccine against the 2019 coronavirus sickness. The lack of anti-vector immunity, the infrequent occurrence of insertional mutagenesis associated with it, and its therapeutic efficacy all contribute to this approval. In addition, it has an edge over traditional DNA vaccines due to its quick production method. A review was conducted based on the available online literature. The procedures used to generate mRNA vaccine in vitro are described in detail in this review. A plasmid containing the super folder green fluorescent protein and the receptor-binding domain present in the coronavirus spike protein is used as an example. A notice for further information on the use of a viral vector in the production of these vaccines is also included.
